We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

New Cas9 Enzyme Reduces CRISPR Off-target Effects Without Significant Loss of On-target Activity

Product News   Aug 03, 2017

 
New Cas9 Enzyme Reduces CRISPR Off-target Effects Without Significant Loss of On-target Activity
FURTHER INFORMATION
 
 
Advertisement
 

Related Product News

ERS Genomics Announces Agreement With Applied StemCell To Commercialize CRISPR Gene Editing Solutions

Product News

ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property announced it has signed an agreement with Applied StemCell, Inc., a leading provider of stem cell, animal model, antibody discovery services and reagents to commercialize CRISPR gene editing.

READ MORE

Univercells Technologies introduces the NevoLine™ Upstream Platform

Product News

This upstream manufacturing platform is suitable for multiple viral applications to support the booming gene therapy market and offer a cost-effective tool for rapid response to emerging infectious diseases.

READ MORE

Arctoris and Syntekabio Form Drug Discovery Research Partnership

Product News

The first project under the agreement sees the two companies work together to assess small molecule therapeutics for COVID-19.

READ MORE

Like what you just read? You can find similar content on the communities below.

Biopharma

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE